Patient outcomes according to aetiological groups
| Idiopathic NSIP | UCTD# | CTDs | cHP | p-value | |
|---|---|---|---|---|---|
| Subjects | 51 | 32 | 29 | 15 | |
| Duration of follow-up months | 66.7±58.0 | 64.3±49.3 | 67.1±61.7 | 45.8±31.5 | 0.716 |
| Treatment at some point during follow-up | |||||
| Corticosteroids | 39 | 26 | 21 | 13 | 0.849 |
| Azathioprine | 20 | 14 | 12 | 6 | 0.966 |
| Cyclophosphamide | 12 | 6 | 11 | 4 | 0.352 |
| Mycophenolate mofetil | 8 | 8 | 7 | 1 | 0.341 |
| Response to first or second-line treatment n/N | 10/39 | 10/25 | 11/23 | 3/14 | 0.219 |
| Long-term evolution of PFTs | |||||
| Subjects | 43 | 26 | 23 | 13 | |
| Interval between PFTs years | 4.6±3.9 | 5.2±4.0 | 5.6±3.8 | 3.7±2.4 | 0.485 |
| Annual FVC decline % | −3.2±7.2 | −1.5±3.9 | −2.0±3.5 | −2.0±4.6 | 0.562 |
| Annual DLCO decline % | −4.5±13.2 | −1.5±5.2 | −0.8±1.9 | −3.1±7.2 | 0.304 |
| Improvement/stability/worsening | 6/11/26 | 5/8/13 | 1/12/10 | 2/4/7 | 0.396 |